Allergic rhinitis and adenoid hypertrophy in children: Rational ways of therapy

In the structure of general morbidity, respiratory allergic pathology occupies the third position, but according to forecasts of the World Health Organization, by 2050 it will take first place. According to statistics, the prevalence of AR in Russia is up to 24%. The number of AR cases in children is increasing, and almost half of AR patients develop symptoms before the age of 6 years. AR negatively affects the quality of life, school performance, and overall health. An important comorbid condition in allergic rhinitis in children is adenoid hypertrophy, which is closely related to the allergic process in the nasal cavity. The use of intranasal corticosteroids (mometasone furoate) as monotherapy significantly reduces both the symptoms of allergic rhinitis and the size of the pharyngeal tonsil. In combination with the leukotriene inhibitor montelukast mometasone furoate allows for better results and fewer relapses compared to monotherapy with mometasone intranasal administration alone. According to the analyzed clinical observations in patients with allergic rhinitis and adenoid hypertrophy, mometasone furoate and mometasone furoate and montelukast showed a good clinical effect. Based on the analysis of systematic reviews on the etiology, clinic and diagnosis of allergic rhinitis in combination with adenoid hypertrophy, data on the relationship between adenoid hypertrophy and allergic rhinitis and methods of their correction, as well as clinical studies on the efficacy and safety of mometasone furoate and montelukast, it is concluded that their use in a complex treatment of allergic rhinitis and adenoid hypertrophy in children.

1. Garaschenko TI, Boikova NE. Impaired nasal breathing and allergic rhinitis in children. Meditsinskiy Sovet. 2015;(6):72–78. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/197/.

2. Ревякина ВА, Дайхес НА, Геппе НА. (ред.). РАДАР. Аллергический ринит у детей: рекомендации и алгоритм при детском аллергическом рините. 4-е изд., перераб. и доп. М.: Медиа Медичи; 2023. 112 с. Режим доступа: https://mediamedichi.ru/radar_izdanie/.

3. Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации: М.; 2024. 88 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/261_2.

4. Bousquet J, Schünemann HJ, Togias A, Bachert C, Erhola M, Hellings PW et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. https://doi.org/10.1016/j.jaci.2019.06.049.

5. Khaitov MR, Namazova-Baranova LS, Ilyina NI, Kurbacheva OM, Bachert C, Hellings PW et al. 2019 ARIA: care pathways for allergic rhinitis in Russia. Russian Journal of Allergy. 2020;17(1): 7–22. (In Russ.) https://doi.org/10.36691/RAJ.2020.17.1.001.

6. Khaitov MR, Namazova-Baranova LS, Chuchalin AG, Dayhes NA, Ilina NI, Kurbacheva ОМ et al. ARIA 2016: integrated care pathways for predictive medicine across the life cycle. Russian Journal of Allergy. 2017;14(3):46–54. (In Russ.) Available at: https://www.elibrary.ru/zfuacr.

7. Намазова-Баранова ЛС, Алексеева АА, Алтунин ВВ, Антонова ЕВ, Аршба ЭА, Ахмедуллина ДИ и др. Аллергия у детей: от теории – к практике. М.: ПедиатрЪ; 2011. 668 с. Режим доступа: https://www.elibrary.ru/qmmlxp.

8. Tarasova GD, Garashchenko TI, Sapozhnikov YaM. Allergic rhinitis in children’s practice. Meditsinskiy Sovet. 2019(17):192–197. (In Russ.) https://doi.org/10.21518/2079-701x-2019-17-192-197.

9. Licari A, Magri P, De Silvestri A, Giannetti A, Indolfi C, Mori F et al. Epidemiology of Allergic Rhinitis in Children: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract. 2023;11(8):2547–2556. https://doi.org/10.1016/j.jaip.2023.05.016.

10. Adamko DJ, Hildebrand KJ. The changing epidemiology of paediatric childhood asthma and allergy in different regions of the world. Front Allergy. 2025;6:1584928. https://doi.org/10.3389/falgy.2025.1584928.

11. Burbank AJ. Climate Change and the Future of Allergies and Asthma. Curr Allergy Asthma Rep. 2025;25(1):20. https://doi.org/10.1007/s11882-025-01201-0.

12. Wise SK, Damask C, Greenhawt M, Oppenheimer J, Roland LT, Shaker MS et al. A Synopsis of Guidance for Allergic Rhinitis Diagnosis and Management From ICAR 2023. J Allergy Clin Immunol Pract. 2023;11(3):773–796. https://doi.org/10.1016/j.jaip.2023.01.007.

13. Epstein TEG, Rorie AC, Ramon GD, Keswani A, Bernstein J, Codina R et al. Impact of climate change on aerobiology, rhinitis, and allergen immunotherapy: Work Group Report from the Aerobiology, Rhinitis, Rhinosinusitis & Ocular Allergy, and Immunotherapy, Allergen Standardization & Allergy Diagnostics Committees of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025;155(6):1767–1782.e2. https://doi.org/10.1016/j.jaci.2025.01.048.

14. Cohen B. Allergic Rhinitis. Pediatr Rev. 2023;44(10):537–550. https://doi.org/10.1542/pir.2022-005618.

15. Cheng M, Dai Q, Liu Z, Wang Y, Zhou C. New progress in pediatric allergic rhinitis. Front Immunol. 2024;15:1452410. https://doi.org/10.3389/fimmu.2024.1452410.

16. Garashchenko TI. Modern therapy of allergic rhinitis in children. RMJ. 2002;10(5):273–278. (In Russ.) Available at: https://www.rmj.ru/articles/allergologiya/Sovremennaya_terapiya_allergicheskih_rinitov_u_detey/.

17. Korkmazov MYu, Lengina MA, Dubinets ID, Korkmazov AM, Smirnov A. Quality of life of children with allergic rinitis and ways of correction. Meditsinskiy Sovet. 2023;17(19):115–124. (In Russ.) https://doi.org/10.21518/ms2023-379.

18. Voss Vahlkvist S, Romano Rodriguez M, Pedersen M, Houmann Petersen T. The impact of allergic rhinitis on future educational outcomes: a Danish real-world register study. Curr Med Res Opin. 2025;41(2):261–268. https://doi.org/10.1080/03007995.2025.2452518.

19. Shilenkova VV. Allergic rhinitis and comorbid diseases. Otorhinolaryngologist’s view. Case report. Consilium Medicum. 2022;24(9):612–616. (In Russ.) https://doi.org/10.26442/20751753.2022.9.201868.

20. Карпова ЕП, Юнусов АС, Тулупов ДА, Карнеева ОВ, Зябкин ИВ, Полунин ИМ и др. Гипертрофия аденоидов, гипертрофия небных миндалин: клинические рекомендации. М.; 2024. 44 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/662_2.

21. Карнеева ОВ, Юнусов АС, Гуров АВ, Абдулкеримов ХТ, Рязанцев СВ, Карпова ЕП и др. Острый синусит: клинические рекомендации. М.; 2024. 49 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/313_3.

22. Turovskaya AA, Kostina EM, Trushina EYu, Orlova EA. Allergic rhinitis and adenoid hypertrophy: relationship, modern view on diagnosis and therapy. Practical Allergology. 2023;(1):56–60. (In Russ.) Available at: https://rumedo.ru/uploads/materials/07b9ac60d51b1d4bd93007a5ebb6b93e.pdf.

23. Evcimik MF, Dogru M, Cirik AA, Nepesov MI. Adenoid hypertrophy in children with allergic disease and influential factors. Int J Pediatr Otorhinolaryngol. 2015;79(5):694–697. https://doi.org/10.1016/j.ijporl.2015.02.017.

24. Cho KS, Kim SH, Hong SL, Lee J, Mun SJ, Roh YE et al. Local Atopy in Childhood Adenotonsillar Hypertrophy. Am J Rhinol Allergy. 2018;32(3):160–166. https://doi.org/10.1177/1945892418765003.

25. Yang Y, Li X, Ma Q, Fu Z, Su K. Detecting epidemiological relevance of adenoid hypertrophy, rhinosinusitis, and allergic rhinitis through an Internet search. Eur Arch Otorhinolaryngol. 2022;279(3):1349–1355. https://doi.org/10.1007/s00405-021-06885-4.

26. Modrzyński M, Zawisza E, Mazurek H. The influence of medical treatment of the perennial allergic rhinitis on the adenoid size in children. Otolaryngol Pol. 2006;60(4):543–550. (In Polish) Available at: https://pubmed.ncbi.nlm.nih.gov/17152807/.

27. Drozdova MV, Karelin AV, Larionova SN, Bykova AV, Garifullin MM. The probable causes of the absence of pharyngeal tonsil involution in adolescents. Rossiiskaya Otorinolaringologiya. 2019;18(4):39–43. (In Russ.) https://doi.org/10.18692/1810-4800-2019-4-39-43.

28. D’Elia C, Gozal D, Bruni O, Goudouris E, Meira E Cruz M. Allergic rhinitis and sleep disorders in children – coexistence and reciprocal interactions. J Pediatr. 2022;98(5):444–454. https://doi.org/10.1016/j.jped.2021.11.010.

29. Agüero CA, Sarraquigne MP, Parisi CAS, Mariño AI, López K, Menéndez Porfirio B et al. Allergic rhinitis in pediatrics: recommendations for diagnosis and treatment. Arch Argent Pediatr. 2023;121(2):e202202894. (In Spanish) https://doi.org/10.5546/aap.2022-02894.

30. Asmanov AI, Konyukova NG, Pivneva ND, Grebennikova YuV, Pampura AN. Comprehensive treatment method for children with allergic rhinitis. RMJ. Medical Review. 2021;5(5):348–352. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Kompleksnyy_podhod_klecheniyu_detey_sallergicheskim_rinitom/.

31. Kudryavtseva AV, Ksenzova LD. Allergic rhinitis in pediatrics: local therapy. Lechaschi Vrach. 2021;(4):16–20. (In Russ.) https://doi.org/10.51793/OS.2021.11.72.003.

32. Garashchenko TI, Tarasova GD. Inhaled glucocorticosteroids in otorhinolaryngology. Meditsinskiy Sovet. 2020;(1):50–58. (In Russ.) https://doi.org/10.21518/2079-701x-2020-1-50-58.

33. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1 Suppl.):S26–S31. https://doi.org/10.1067/mai.2001.115563.

34. Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. https://doi.org/10.1186/s40248-016-0054-3.

35. Ciprandi G, Varricchio A. The relevance of the Mometasone furoate nasal spray in clinical practice. J Biol Regul Homeost Agents. 2018;32(4):1051–1054. Available at: https://www.biolifesas.org/EN/Y2018/V32/I4/1051.

36. Mak KK, Ku MS, Lu KH, Sun HL, Lue KH. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol. 2013;54(4):239–245. https://doi.org/10.1016/j.pedneo.2013.01.007.

37. Sharpe SA, Sandweiss V, Tuazon J, Giordano M, Witchey-Lakshmanan L, Hart J, Sequeira J. Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003;29(9):1005–1012. https://doi.org/10.1081/ddc-120025457.

38. Ahmed MR, Abou-Halawa AS, Ibrahim IH, Zittoon RF, Makary EFY. Effect of topical mometasone furoate on adenoidal lymphoid tissue: a light microscopic study. J Laryngol Otol. 2019;133(2):106–109. https://doi.org/10.1017/S0022215118002268.

39. Chohan A, Lal A, Chohan K, Chakravarti A, Gomber S. Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children. Int J Pediatr Otorhinolaryngol. 2015;79(10):1599–1608. https://doi.org/10.1016/j.ijporl.2015.07.009.

40. Arslan E, Tulaci KG, Canakci H, Arslan S, Yazici H. Evaluation of the intranasal steroid treatment outcomes in adenoid tissue hypertrophy with or without allergic rhinitis. Am J Otolaryngol. 2021;42(4):102983. https://doi.org/10.1016/j.amjoto.2021.102983.

41. Ghafar MHA, Mohamed H, Mohammad NMY, Mohammad ZW, Madiadipoera T, Wang Y, Abdullah B. Mometasone furoate intranasal spray is effective in reducing symptoms and adenoid size in children and adolescents with adenoid hypertrophy. Acta Otorrinolaringol Esp. 2020;71(3):147–153. https://doi.org/10.1016/j.otorri.2019.04.004.

42. Roushdy MM, Jalil AAA, Saeed AM. Mometasone Furoate Use for Recurrent Adenoid Hypertrophy: Randomized Controlled Clinical Trial. Indian J Otolaryngol Head Neck Surg. 2023;75(3):1639–1646. https://doi.org/10.1007/s12070-023-03539-1.

43. Авдеев СН, Намазова-Баранова ЛС, Ильина НИ, Вишнева ЕА, Зырянов СК, Каркашадзе ГА и др. Применение антилейкотриеновых препаратов в лечении аллергических болезней дыхательных путей: методические рекомендации для специалистов педиатров, оториноларингологов, аллергологов и врачей общей практики. М.; 2024. 70 с. Режим доступа: https://www.pediatr-russia.ru/information/klin-rek/proekty-metodicheskikh-rekomendatsiy/Проект%20метод%20рек%20АЛТР%2029.02.2024.pdf.

44. Mayoral K, Lizano-Barrantes C, Zamora V, Pont A, Miret C, Barrufet C et al. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(170):230124. https://doi.org/10.1183/16000617.0124-2023.

45. Wintzell V, Brenner P, Halldner L, Rhedin S, Gong T, Almqvist C. Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children. JAMA Pediatr. 2025;179(4):418–427. https://doi.org/10.1001/jamapediatrics.2024.5429.

46. Liu A, Zhang Y, Lin Y, Li X, Wang S, Pu W et al. A rat model of adenoid hypertrophy constructed by using ovalbumin and lipopolysaccharides to induce allergy, chronic inflammation, and chronic intermittent hypoxia. Animal Model Exp Med. 2025;8(2):353–362. https://doi.org/10.1002/ame2.12396.

47. Vayman OA. Prospects for the use of antileukotriene drugs in children with pathology of the lymphopharyngeal ring. Rossiiskaya Otorinolaringologiya. 2009;(2):184–189. (In Russ.) Available at: https://med-click.ru/uploads/files/docs/perspektivy-primeneniya-antileykotrienovyh-preparatov-u-detey-s-patologiey-limfoglotochnogo-koltsa.pdf.

48. Chang HH, Zhang XY, An L, Dang PH, Luo J, Wang J. Novel Classification System of Adenoids Based on Appearance and Its Relationship with Drug Therapy. Int Arch Allergy Immunol. 2023;184(7):634–642. https://doi.org/10.1159/000528445.

49. Almutairi RH, Albesher MB, Alboqami RA, Al-Fahd AZ, Fahad Z Alshehri R et al. Comparative efficacy of intranasal mometasone furoate monotherapy or combination therapy with montelukast in pediatric adenoid hypertrophy: A systematic review and meta-analysis of randomized clinical trials. Int J Pediatr Otorhinolaryngol. 2025;192:112310. https://doi.org/10.1016/j.ijporl.2025.112310.

50. Joseph M, Krishna MM, Franco AJ, Jekov L, Sudo RYU, Cabral TDD. Efficacy of combination therapy with mometasone and montelukast versus mometasone alone in treatment of adenoid hypertrophy in children: A systematic review and meta-analysis. Am J Otolaryngol. 2025;46(1):104566. https://doi.org/10.1016/j.amjoto.2024.104566.